Study examines attitudes toward long-acting injectable HIV therapy among women

January 07, 2021

A study led by Columbia University Mailman School of Public Health researchers examines attitudes toward long-acting injectable (LAI) HIV therapies, among women with a history of injection--including medical purposes and substance use. The findings appear in the journal AIDS Patient Care and STDs.

Currently, most HIV therapies for treatment and prevention (pre-exposure prophylaxis, PrEP) necessitate daily pills, which pose barriers to adherence. Recently, however, LAI for HIV has emerged as an alternative with the potential to boost adherence, although little research has been done on how people with a history of injection feel about these new forms of injectable HIV therapy. There 258,000 women in the United States living with HIV.

The study involved interviews with 89 women across six different sites in the United States. Overall, participants highlighted how LAIs may improve adherence by freeing women of treatment fatigue and reminders associated with daily pill-taking, thus eliminating potential stigma, and facilitating confidentiality. Most women with a history of periodic injectable medication (such as birth control) would prefer LAI, but those with other frequent injections (such as for diabetes) who expressed a desire to limit the number and frequency of injections and clinic visits might not. Women with a history of injection drug use expressed mixed sentiments: some feared LAI might trigger a recurrence while others felt that familiarity with needles would predispose people who use injection drugs towards LAI.

The authors write that LAI HIV therapies would ideally coincide with existing LAI treatments (e.g., birth control) to minimize inconvenience and the need for multiple clinic visits, an approach currently used in some clinics that co-locate care for HIV and substance use.

"Future research needs to address injection-related concerns, and develop patient-centered approaches to help providers work with their patients to best identify which women could most benefit from LAI use," says first author Morgan Philbin, PhD, assistant professor of sociomedical sciences at Columbia Mailman School. "As LAI ART for HIV treatment and prevention is scaled-up, systems must be created for women and providers to collaborate in order to best identify which women might need additional support for LAI use and which might be better candidates for daily pills."

The researchers conducted in-depth interviews at six sites (New York, NY; Chicago, IL; San Francisco, CA; Atlanta, GA; Chapel Hill, NC; Washington, D.C.) as part of the Women's Interagency HIV Study, including women living with HIV and women at risk for HIV.
A complete list of authors, their affiliations, and funding sources is available online, as part of the published article. Co-author Adaora A. Adimora-has received funding from Viiv, Merck, and Gilead, including a grant from Gilead. Co-author Anandi N. Sheth declares that Gilead has given research grants to her institution, but none are related to her current work.

Columbia University's Mailman School of Public Health

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to